Patient case report on the use of the NanoTherm® therapy for the treatment of recurrent glioblastoma
- Primary tumor diagnosis of glioblastoma on June 21, 2006, WHO Grade IV, frontal left
- Resection on July 27, 2006
- Radiotherapy from August 30 – October 1, 2006
- Diagnosis of relapse on November 16, 2006
On July 21, 2006 a histologically verified left glioblastoma, WHO Grade IV, was diagnosed in a 24-year-old patient. On July 27, 2006 the tumor measuring 5.5 cm x 5 cm was totally resected. From August 30 – October 1, 2006 radiotherapy (2 Gy/d) was performed with a total dose of 50 Gy. However, on November 16, 2006, a relapse with a tumor volume of 5.3 ml was diagnosed via MRI.
Decision for NanoTherm® Therapy
After postoperative FET-PET and CT on January 24, 2007, the decision was made to treat with NanoTherm® therapy in combination with simultaneous radiotherapy. Prior to the instillation of the nanoparticles on January 30, 2007 an MRI was conducted in order to localize the tumor.
- Instillation of 3.7 ml NanoTherm® in 5 depots on January 31, 2007
- Preoperative MRI (January 30, 2007) and postoperative CT (February 5, 2007) were performed for the simulation of temperature distribution in the different tumor regions using a specific software
- Treatment of patient with alternating magnetic field in the NanoActivator® (February 7 - February 23, 2007: twice a week 1 hour over a period of 3 weeks, in total 6 sessions)
- Treatment with 2 Gy for 10 days (February 7 - February 27, 2007) and 2.5 Gy for 4 days (total dose 30 Gy) concomitant to the 3-weeks NanoTherm® therapy
During this therapy, the patient appeared twice to feel disoriented for a few minutes. Apart from this, the patient did not complain of any further side effects.
- The follow-up CT scans showed no indication of tumor relapse at 3, 4, 8, 12, 16, 19 and 26 months after the end of the therapy
- Last contact: January 2011, the patient is alive (47 months)
NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide certification (CE mark) as medical devices for the treatment of brain tumors. NanoTherm® therapy is currently available to national and foreign patients in dedicated hospitals in Germany.